Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 14/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.46 |
| ▸ | IDH2 | P48735 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10312083 | 0.88 | IGF1R (0.43) | IGF1RNTRK1 | |
| SCHEMBL10312181 | 0.87 | IDH2 (0.48) | IGF1RIDH2NTRK1HRH4 | |
| SCHEMBL10312154 | 0.86 | IGF1R (0.45) | IGF1RCCNA2CDK2CCNA1 | |
| SCHEMBL10312126 | 0.85 | IDH2 (0.47) | IGF1RIDH2MEN1KMT2AHRH4 | |
| SCHEMBL10312180 | 0.83 | HRH4 (0.48) | IGF1RCCNA2CDK2CCNA1IDH2 | |
| SCHEMBL10312076 | 0.83 | HRH4 (0.59) | IGF1RCCNA2CDK2CCNA1IDH2 | |
| SCHEMBL10312191 | 0.83 | IGF1R (0.51) | IGF1RCCNA2CDK2CCNA1NTRK1 | |
| SCHEMBL10312178 | 0.82 | CCNA2 (0.45) | IGF1RCCNA2CDK2CCNA1NEK1 | |
| SCHEMBL10312080 | 0.82 | IDH2 (0.51) | IGF1RCCNA2CDK2CCNA1IDH2 | |
| SCHEMBL10312185 | 0.82 | NTRK1 (0.47) | IGF1RCCNA2CDK2CCNA1NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440055-B1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY LLC (US) | 2015-03-11 | — | — | EP | disclosed |
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | STK25, STK35, SGK2 | IGF1R 1148/4885CCNA2 1229/4885CDK2 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.